AXGN earnings: next report 2026-07-29, real EPS beat/miss history, analyst consensus Buy, P/E -62.27. Updated 2026-07-23.
AxoGen (AXGN) Research Hub
AxoGen (AXGN) trades on NASDAQ, US in the Healthcare (Medical - Devices) sector. As of 2026-09-11, shares last closed at 42.16 USD (-10.81%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -62.27, market cap 2.08B. This hub links to the full technical, earnings and options research available for AXGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Devices) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 42.16 USD (-10.81%) |
| 52-week range | 38.27 USD – 52.43 USD |
| Trend regime | Range |
| 14-day RSI | 39.5 (Bearish) |
| Trailing P/E | -62.27 |
| Market cap | 2.08B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-29 |
Available research for AXGN
Covered Call on AXGN: how it works, illustrative setup around the real 42.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on AXGN: how it works, illustrative setup around the real 42.16 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on AXGN: how it works, illustrative setup around the real 42.16 USD price, max profit/loss, breakeven and when to use it. Educational.
AXGN technical analysis: range, last 42.16 USD, RSI 39.5, 52w range 38.27 USD–52.43 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is AXGN in?
AxoGen (AXGN) is classified under Healthcare (Medical - Devices), listed on NASDAQ, US.
Is AXGN in an uptrend or downtrend?
As of 2026-09-11, AXGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is AXGN's trailing P/E ratio?
AXGN's trailing P/E is -62.27, with a market cap of 2.08B. See the earnings research page for full valuation detail.
When does AXGN next report earnings?
AXGN is next scheduled to report earnings on 2026-07-29, with a consensus EPS estimate of 0.09 USD.